m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00625)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
NKX3-1
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | LX2 cell line | Homo sapiens |
Treatment: shMETTL3 LX2 cells
Control: shLuc LX2 cells
|
GSE207909 | |
Regulation |
|
logFC: 1.12E+00 p-value: 7.44E-16 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between NKX3-1 and the regulator | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Regulation | logFC: 7.11E+00 | GSE60213 |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | Knock-down of YTHDF2 or METTL3 significantly induced the expression of LHPP and Homeobox protein Nkx-3.1 (NKX3-1) at both mRNA and protein level with inhibited phosphorylated AKT. YTHDF2 mediates the mRNA degradation of the tumor suppressors LHPP and NKX3-1 in m6A-dependent way to regulate AKT phosphorylation-induced tumor progression in prostate cancer. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Prostate cancer | ICD-11: 2C82 | ||
Pathway Response | Oxidative phosphorylation | hsa00190 | ||
In-vitro Model | VCaP | Prostate carcinoma | Homo sapiens | CVCL_2235 |
RWPE-1 | Normal | Homo sapiens | CVCL_3791 | |
PC-3 | Prostate carcinoma | Homo sapiens | CVCL_0035 | |
DU145 | Prostate carcinoma | Homo sapiens | CVCL_0105 | |
22Rv1 | Prostate carcinoma | Homo sapiens | CVCL_1045 | |
In-vivo Model | Approximately 2 × 106 PCa cells (PC-3 shNC, shYTHDF2, shMETTL3 cell lines) per mouse suspended in 100 uL PBS were injected in the flank of male BALB/c nude mice (4 weeks old). During the 40-day observation, the tumor size (V = (width2×length ×0.52)) was measured with vernier caliper. Approximately 1.5 × 106 PCa cells suspended in 100 uL of PBS (PC-3 shNC, shYTHDF2, and shMETTL3 cell lines) per mouse were injected into the tail vein of male BALB/c nude mice (4 weeks old). The IVIS Spectrum animal imaging system (PerkinElmer) was used to evaluate the tumor growth (40 days) and whole metastasis conditions (4 weeks and 6 weeks) with 100 uL XenoLight D-luciferin Potassium Salt (15 mg/ml, Perkin Elmer) per mouse. Mice were anesthetized and then sacrificed for tumors and metastases which were sent for further organ-localized imaging as above, IHC staining and hematoxylin-eosin (H&E) staining. | |||
YTH domain-containing family protein 2 (YTHDF2) [READER]
Representative RNA-seq result indicating the expression of this target gene regulated by YTHDF2 | ||
Cell Line | GSC11 cell line | Homo sapiens |
Treatment: siYTHDF2 GSC11 cells
Control: siControl GSC11 cells
|
GSE142825 | |
Regulation |
|
logFC: 9.36E-01 p-value: 4.17E-02 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between NKX3-1 and the regulator | ||
Cell Line | Hela | Homo sapiens |
Regulation | logFC: 1.20E+00 | GSE49339 |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | Knock-down of YTHDF2 or METTL3 significantly induced the expression of LHPP and Homeobox protein Nkx-3.1 (NKX3-1) at both mRNA and protein level with inhibited phosphorylated AKT. YTHDF2 mediates the mRNA degradation of the tumor suppressors LHPP and NKX3-1 in m6A-dependent way to regulate AKT phosphorylation-induced tumor progression in prostate cancer. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Prostate cancer | ICD-11: 2C82 | ||
Pathway Response | Oxidative phosphorylation | hsa00190 | ||
In-vitro Model | VCaP | Prostate carcinoma | Homo sapiens | CVCL_2235 |
RWPE-1 | Normal | Homo sapiens | CVCL_3791 | |
PC-3 | Prostate carcinoma | Homo sapiens | CVCL_0035 | |
DU145 | Prostate carcinoma | Homo sapiens | CVCL_0105 | |
22Rv1 | Prostate carcinoma | Homo sapiens | CVCL_1045 | |
In-vivo Model | Approximately 2 × 106 PCa cells (PC-3 shNC, shYTHDF2, shMETTL3 cell lines) per mouse suspended in 100 uL PBS were injected in the flank of male BALB/c nude mice (4 weeks old). During the 40-day observation, the tumor size (V = (width2×length ×0.52)) was measured with vernier caliper. Approximately 1.5 × 106 PCa cells suspended in 100 uL of PBS (PC-3 shNC, shYTHDF2, and shMETTL3 cell lines) per mouse were injected into the tail vein of male BALB/c nude mice (4 weeks old). The IVIS Spectrum animal imaging system (PerkinElmer) was used to evaluate the tumor growth (40 days) and whole metastasis conditions (4 weeks and 6 weeks) with 100 uL XenoLight D-luciferin Potassium Salt (15 mg/ml, Perkin Elmer) per mouse. Mice were anesthetized and then sacrificed for tumors and metastases which were sent for further organ-localized imaging as above, IHC staining and hematoxylin-eosin (H&E) staining. | |||
Prostate cancer [ICD-11: 2C82]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | Knock-down of YTHDF2 or METTL3 significantly induced the expression of LHPP and Homeobox protein Nkx-3.1 (NKX3-1) at both mRNA and protein level with inhibited phosphorylated AKT. YTHDF2 mediates the mRNA degradation of the tumor suppressors LHPP and NKX3-1 in m6A-dependent way to regulate AKT phosphorylation-induced tumor progression in prostate cancer. | |||
Responsed Disease | Prostate cancer [ICD-11: 2C82] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | Oxidative phosphorylation | hsa00190 | ||
In-vitro Model | VCaP | Prostate carcinoma | Homo sapiens | CVCL_2235 |
RWPE-1 | Normal | Homo sapiens | CVCL_3791 | |
PC-3 | Prostate carcinoma | Homo sapiens | CVCL_0035 | |
DU145 | Prostate carcinoma | Homo sapiens | CVCL_0105 | |
22Rv1 | Prostate carcinoma | Homo sapiens | CVCL_1045 | |
In-vivo Model | Approximately 2 × 106 PCa cells (PC-3 shNC, shYTHDF2, shMETTL3 cell lines) per mouse suspended in 100 uL PBS were injected in the flank of male BALB/c nude mice (4 weeks old). During the 40-day observation, the tumor size (V = (width2×length ×0.52)) was measured with vernier caliper. Approximately 1.5 × 106 PCa cells suspended in 100 uL of PBS (PC-3 shNC, shYTHDF2, and shMETTL3 cell lines) per mouse were injected into the tail vein of male BALB/c nude mice (4 weeks old). The IVIS Spectrum animal imaging system (PerkinElmer) was used to evaluate the tumor growth (40 days) and whole metastasis conditions (4 weeks and 6 weeks) with 100 uL XenoLight D-luciferin Potassium Salt (15 mg/ml, Perkin Elmer) per mouse. Mice were anesthetized and then sacrificed for tumors and metastases which were sent for further organ-localized imaging as above, IHC staining and hematoxylin-eosin (H&E) staining. | |||
Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | Knock-down of YTHDF2 or METTL3 significantly induced the expression of LHPP and Homeobox protein Nkx-3.1 (NKX3-1) at both mRNA and protein level with inhibited phosphorylated AKT. YTHDF2 mediates the mRNA degradation of the tumor suppressors LHPP and NKX3-1 in m6A-dependent way to regulate AKT phosphorylation-induced tumor progression in prostate cancer. | |||
Responsed Disease | Prostate cancer [ICD-11: 2C82] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | Oxidative phosphorylation | hsa00190 | ||
In-vitro Model | VCaP | Prostate carcinoma | Homo sapiens | CVCL_2235 |
RWPE-1 | Normal | Homo sapiens | CVCL_3791 | |
PC-3 | Prostate carcinoma | Homo sapiens | CVCL_0035 | |
DU145 | Prostate carcinoma | Homo sapiens | CVCL_0105 | |
22Rv1 | Prostate carcinoma | Homo sapiens | CVCL_1045 | |
In-vivo Model | Approximately 2 × 106 PCa cells (PC-3 shNC, shYTHDF2, shMETTL3 cell lines) per mouse suspended in 100 uL PBS were injected in the flank of male BALB/c nude mice (4 weeks old). During the 40-day observation, the tumor size (V = (width2×length ×0.52)) was measured with vernier caliper. Approximately 1.5 × 106 PCa cells suspended in 100 uL of PBS (PC-3 shNC, shYTHDF2, and shMETTL3 cell lines) per mouse were injected into the tail vein of male BALB/c nude mice (4 weeks old). The IVIS Spectrum animal imaging system (PerkinElmer) was used to evaluate the tumor growth (40 days) and whole metastasis conditions (4 weeks and 6 weeks) with 100 uL XenoLight D-luciferin Potassium Salt (15 mg/ml, Perkin Elmer) per mouse. Mice were anesthetized and then sacrificed for tumors and metastases which were sent for further organ-localized imaging as above, IHC staining and hematoxylin-eosin (H&E) staining. | |||